Naturally occurring SARS-CoV-2 gene deletions close to the spike S1/S2 cleavage site in the viral quasispecies of COVID19 patients

Emerg Microbes Infect. 2020 Dec;9(1):1900-1911. doi: 10.1080/22221751.2020.1806735.

Abstract

The SARS-CoV-2 spike (S) protein, the viral mediator for binding and entry into the host cell, has sparked great interest as a target for vaccine development and treatments with neutralizing antibodies. Initial data suggest that the virus has low mutation rates, but its large genome could facilitate recombination, insertions, and deletions, as has been described in other coronaviruses. Here, we deep-sequenced the complete SARS-CoV-2 S gene from 18 patients (10 with mild and 8 with severe COVID-19), and found that the virus accumulates deletions upstream and very close to the S1/S2 cleavage site (PRRAR/S), generating a frameshift with appearance of a stop codon. These deletions were found in a small percentage of the viral quasispecies (2.2%) in samples from all the mild and only half the severe COVID-19 patients. Our results suggest that the virus may generate free S1 protein released to the circulation. We suggest that natural selection has favoured a "Don't burn down the house" strategy, in which free S1 protein may compete with viral particles for the ACE2 receptor, thus reducing the severity of the infection and tissue damage without losing transmission capability.

Keywords: NGS; SARS-CoV-2; deletions; diversity; quasispecies; respiratory virus.

MeSH terms

  • Adult
  • Aged
  • Betacoronavirus / genetics*
  • COVID-19
  • Computational Biology
  • Coronavirus Infections / virology*
  • Female
  • Gene Deletion
  • Genome, Viral / genetics*
  • High-Throughput Nucleotide Sequencing
  • Humans
  • Male
  • Middle Aged
  • Pandemics
  • Pneumonia, Viral / virology*
  • Quasispecies / genetics*
  • RNA Cleavage
  • Respiratory Tract Infections / virology*
  • SARS-CoV-2
  • Sequence Analysis, RNA
  • Spike Glycoprotein, Coronavirus / genetics*

Substances

  • Spike Glycoprotein, Coronavirus

Grants and funding

This study was partially supported by the Direcció General de Recerca i Innovació en Salut (DGRIS) Catalan Health Ministry Generalitat de Catalunya through Vall d'Hebron Institut de Recerca (VHIR); European Development Regional Fund (ERDF) “A way to achieve Europe” by Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0003); and Centro para el Desarrollo Tecnológico Industrial (CDTI) from the Spanish Ministry of Economy and Business, grant number IDI-20200297.